BACKGROUND: We report the radiation-induced late morbidity observed in our prospective series of Wilms tumor patients treated at the Second University of Naples. METHODS: From April 1981 to April 2000, 98 patients were referred at our institution for treatment of Wilms tumor. Among them, 51 underwent radiotherapy and 34 patients had a minimum follow-up of 5 years. Doses of irradiation and treatment portals were those recommended by the guidelines of the Italian Association of Haematology and Paediatric Oncology according to risk stratification. All eligible patients were reviewed for follow-up every 6 months. Median follow-up was 181 months (range 60 to 264 months). RESULTS: Eleven out of 34 patients (32%) did not suffer from any significant late side effect. Out of the remaining 23 (68%), 14 (41%) suffered from scoliosis presenting between 60 and 180 months from completion of treatment. Muscular hypoplasia, length inequality, kyphosis, and iliac wing hypoplasia were seen respectively, in 4 (12%), 4 (12%), 5 (15%), and 3 (9%) patients. The incidence of intestinal occlusion was 20%. One patient had chronic renal insufficiency. Four out of 13 female patients reported ovarian failure. Three out of the 7 patients who had radiotherapy to the lung developed radiation-pneumonitis. Radiation-induced heart disease was seen in 3 (9%) patients. Three patients (9%) suffered from second malignancies arising within the irradiated volume. CONCLUSIONS: Our data confirm the high incidence of late radiation morbidity in patients undergoing adjuvant radiotherapy for Wilms tumor. For most organ systems there is a correlation between total dose, morbidity rates, and degree of severity.
BACKGROUND: We report the radiation-induced late morbidity observed in our prospective series of Wilms tumorpatients treated at the Second University of Naples. METHODS: From April 1981 to April 2000, 98 patients were referred at our institution for treatment of Wilms tumor. Among them, 51 underwent radiotherapy and 34 patients had a minimum follow-up of 5 years. Doses of irradiation and treatment portals were those recommended by the guidelines of the Italian Association of Haematology and Paediatric Oncology according to risk stratification. All eligible patients were reviewed for follow-up every 6 months. Median follow-up was 181 months (range 60 to 264 months). RESULTS: Eleven out of 34 patients (32%) did not suffer from any significant late side effect. Out of the remaining 23 (68%), 14 (41%) suffered from scoliosis presenting between 60 and 180 months from completion of treatment. Muscular hypoplasia, length inequality, kyphosis, and iliac wing hypoplasia were seen respectively, in 4 (12%), 4 (12%), 5 (15%), and 3 (9%) patients. The incidence of intestinal occlusion was 20%. One patient had chronic renal insufficiency. Four out of 13 female patients reported ovarian failure. Three out of the 7 patients who had radiotherapy to the lung developed radiation-pneumonitis. Radiation-induced heart disease was seen in 3 (9%) patients. Three patients (9%) suffered from second malignancies arising within the irradiated volume. CONCLUSIONS: Our data confirm the high incidence of late radiation morbidity in patients undergoing adjuvant radiotherapy for Wilms tumor. For most organ systems there is a correlation between total dose, morbidity rates, and degree of severity.
Authors: Conrad V Fernandez; Elizabeth A Mullen; Yueh-Yun Chi; Peter F Ehrlich; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Arnold C Paulino; Thomas E Hamilton; Kenneth W Gow; Zelig Tochner; Fredric A Hoffer; Janice S Withycombe; Robert C Shamberger; Yeonil Kim; James I Geller; James R Anderson; Paul E Grundy; Jeffrey S Dome Journal: J Clin Oncol Date: 2017-12-06 Impact factor: 44.544
Authors: Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening Journal: Cochrane Database Syst Rev Date: 2019-03-11
Authors: Joeri Mul; Enrica Seravalli; Mirjam E Bosman; Cornelis P van de Ven; Annemieke S Littooij; Martine van Grotel; Marry M van den Heuvel-Eibrink; Geert O Janssens Journal: Clin Transl Radiat Oncol Date: 2021-05-03
Authors: Marjolein van Waas; Sebastian J C M M Neggers; Hein Raat; Caroline M van Rij; Rob Pieters; Marry M van den Heuvel-Eibrink Journal: PLoS One Date: 2012-12-14 Impact factor: 3.240
Authors: Dinesh Rakheja; Kenneth S Chen; Yangjian Liu; Abhay A Shukla; Vanessa Schmid; Tsung-Cheng Chang; Shama Khokhar; Jonathan E Wickiser; Nitin J Karandikar; James S Malter; Joshua T Mendell; James F Amatruda Journal: Nat Commun Date: 2014-09-05 Impact factor: 14.919
Authors: Inge van der Velpen; Pamela Schendelaar; Evelyn van Pinxteren-Nagler; Chantal M Mouës-Vink Journal: Plast Reconstr Surg Glob Open Date: 2016-04-21
Authors: Yan Liu; Marie V Nelson; Christopher Bailey; Peng Zhang; Pan Zheng; Jeffrey S Dome; Yang Liu; Yin Wang Journal: Oncogene Date: 2021-06-21 Impact factor: 9.867